Article info

Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme

Authors

  1. Correspondence to Professor Stanley B Cohen, Metroplex Clinical Research Center, Dallas, Texas, USA; arthdoc{at}aol.com
View Full Text

Citation

Cohen SB, van Vollenhoven RF, Winthrop KL, et al
Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme

Publication history

  • Received July 3, 2020
  • Revised October 1, 2020
  • Accepted October 3, 2020
  • First published October 28, 2020.
Online issue publication 
February 11, 2021

Article Versions

  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.